Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'.

What Was Tested

This randomized controlled trial looks at Angiotensin II.

The aims of this study include (i) pursuing data-mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial dataset containing atrial fibrillation (AF) burden scores of patients with many clinical parameters and (ii) revealing possible correlations between the estimated risk factors of AF and other clinical findings or measurements provided in the dataset.

Ranking Instances by Maximizing the Area under a Receiver Operating Characteristics (ROC) Curve (RIMARC) is used to determine the predictive weights (Pw) of baseline variables on the primary endpoint.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

The primary endpoint of the ANTIPAF-AFNET 2 trial was the percentage of days with documented episodes of paroxysmal AF or with suspected persistent AF.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

Chi-square automatic interaction detector algorithm is performed for comparing the results of RIMARC.

What Was Measured

Topics PubMed links to this paper include Age Distribution, Angiotensin Receptor Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents, Atrial Fibrillation, Comorbidity and Data Mining.

Author keywords: Blood urea nitrogen, Creatinine, Machine learning, RIMARC and SF-12.

What This Means in Plain Language

The paper is a randomized and double-blind study of Angiotensin II.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology), a journal based in England.

More context: the Angiotensin II compound page, all human trials.